EP Patent

EP2543372A1 — Medicament for the treatment of liver cancer

Assigned to Helmholtz Zentrum fuer Infektionsforschung HZI GmbH · Expires 2013-01-09 · 13y expired

What this patent protects

The invention provides a pharmaceutical composition comprising Sorafenib in combination with an inhibitor of a specific kinase inhibitor as a medicament for the treatment or prevention of liver cancer.

USPTO Abstract

The invention provides a pharmaceutical composition comprising Sorafenib in combination with an inhibitor of a specific kinase inhibitor as a medicament for the treatment or prevention of liver cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP2543372A1
Jurisdiction
EP
Classification
—
Expires
2013-01-09
Drug substance claim
No
Drug product claim
No
Assignee
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.